A petition filed Feb. 5 alleges that corrosion inhibitors from China are being sold at less than fair value in the U.S. market and benefitting from countervailable subsidies. The alleged dumping margins range from 388.28 percent to 420.32 percent.
The petition covers tolyltriazole and benzotriazole of all grades and forms (including their sodium salt forms), including flakes, granules, pellets, prills, needles, powder, or liquids. The scope includes tolyltriazole/sodium tolyltriazole and benzotriazole/sodium benzotriazole that are combined or mixed with other products, regardless of whether the combining occurs in third countries. Tolyltriazole, sodium tolyltriazole, benzotriazole, and sodium benzotriazole otherwise covered by this petition are not excluded when commingled with tolyltriazole, sodium tolyltriazole, benzotriazole, or sodium benzotriazole from sources other than China.
Tolyltriazole is classified under HTSUS subheading 2933.99.8220, sodium tolyltriazole is classified under HTSUS subheading 2933.99.8290, benzotriazole is classified under HTSUS subheading 2933.99.8210, and sodium benzotriazole is classified under HTSUS subheading 2933.99.8290.
The Department of Commerce and the International Trade Commission will next determine whether to launch AD/CV duty and injury investigations, respectively, on this product. There are strict statutory deadlines associated with these proceedings, so affected companies that wish to protect their interests should contact Sandler, Travis & Rosenberg as soon as possible.
For more information please contact trade attorney Kristen Smith at (202) 730-4965.
Copyright © 2020 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.